Chimerix, Inc. (NASDAQ:CMRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “

CMRX has been the subject of a number of other research reports. Cowen and Company reaffirmed a “hold” rating and set a $6.00 price target on shares of Chimerix in a research report on Friday, April 28th. FBR & Co reaffirmed a “hold” rating and set a $7.00 price target on shares of Chimerix in a research report on Monday, May 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. Chimerix currently has an average rating of “Hold” and an average target price of $7.55.

Shares of Chimerix (CMRX) traded down 1.70% during trading on Tuesday, reaching $5.21. 120,661 shares of the company traded hands. The stock’s 50 day moving average price is $4.93 and its 200-day moving average price is $5.38. The stock’s market cap is $243.05 million. Chimerix has a 12 month low of $3.66 and a 12 month high of $6.64.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.01. Chimerix had a negative return on equity of 24.07% and a negative net margin of 1,221.34%. The firm had revenue of $1.08 million for the quarter, compared to analyst estimates of $1.56 million. On average, equities research analysts expect that Chimerix will post ($1.73) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/11/chimerix-inc-cmrx-downgraded-to-sell-at-zacks-investment-research.html.

Several large investors have recently made changes to their positions in CMRX. Teachers Advisors LLC boosted its stake in shares of Chimerix by 0.3% in the fourth quarter. Teachers Advisors LLC now owns 69,888 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 204 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Chimerix by 3.8% in the first quarter. Bank of Montreal Can now owns 39,300 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 1,448 shares in the last quarter. American International Group Inc. boosted its stake in shares of Chimerix by 7.1% in the first quarter. American International Group Inc. now owns 26,281 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 1,733 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Chimerix by 5.9% in the first quarter. Nationwide Fund Advisors now owns 35,573 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 1,977 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Chimerix by 5.0% in the first quarter. Schwab Charles Investment Management Inc. now owns 133,921 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 6,327 shares in the last quarter. Institutional investors own 66.84% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.